Apolipoprotein

Vupanorsen (Ionis) for reduction of non-HDL in patients with hyperlipidemia already on statin therapy.

WASHINGTON — Treatment with vupanorsen, a novel antisense oligonucleotide targeting hepatic ANGPTL3, achieved modest reductions in non-HDL at 24 weeks at all doses studied, according to results of the TRANSLATE-TIMI 70 trial.

Central arterial stiffening contributed to biomarker evidence of neuroinflammation and neurodegeneration in older adults, according to a community-based observational study published in Neurology.

Men with elevated apolipoprotein A-I levels may be less likely to develop type 2 diabetes, and those with a certain polymorphism may be the best candidates for the prediction of the disease’s development via homeostasis model assessment of insulin resistance and the avoidance of the condition via exercise, according to findings published in Nutrition, Metabolism & Cardiovascular Diseases.

A machine learning program with clinical and coronary CT angiography data identified the top predictors of noncalcified coronary burden in psoriasis, which were markers related to obesity, dyslipidemia and inflammation, according to research in Journal of the American Academy of Dermatology.

In a cohort of adults assessed for sleep issues, those in the highest quartile of apolipoprotein B to apolipoprotein A-I ratio were at the greatest risk for obstructive sleep apnea and insulin resistance, according to findings published in Nutrition, Metabolism & Cardiovascular Diseases.

HILTON HEAD, S.C. — A variant of the apolipoprotein L gene could help explain why patients of African ancestry with lupus typically experience worse disease-related outcomes compared with white patients, according to Ashira Blazer, MD, a rheumatologist and assistant professor at the NYU School of Medicine.